Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks
- 11 April 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 152 (4) , 597-615
- https://doi.org/10.1111/j.1365-2133.2005.06563.x
Abstract
Psoriasis is a chronic, recurrent disease that affects between 1% and 3% of the population. Patients with moderate to severe disease generally require phototherapy (e.g. narrowband ultraviolet B radiation), photochemotherapy (oral psoralen plus ultraviolet A radiation) or systemic agents (e.g. ciclosporin, methotrexate, oral retinoids, fumaric acid esters) to control their disease adequately. In general, these therapeutic modalities have proven to be highly effective in the treatment of psoriasis. However, potentially serious toxicities can limit their long‐term use. Given that there is no standard therapeutic approach for patients with moderate to severe psoriasis, the benefits and risks of phototherapy, photochemotherapy and systemic therapy must be weighed carefully for each patient, and treatment individualized accordingly. This review summarizes the benefits and risks of traditional, nonbiological therapies for moderate to severe chronic plaque psoriasis.Keywords
This publication has 76 references indexed in Scilit:
- Combination therapy to treat moderate to severe psoriasisJournal of the American Academy of Dermatology, 2004
- AAD consensus statement on psoriasis therapiesJournal of the American Academy of Dermatology, 2003
- A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2002
- Treatment of psoriasis. Part 2. Systemic therapiesJournal of the American Academy of Dermatology, 2001
- Antipsoriatic effect of fumaric acid derivatesJournal of the American Academy of Dermatology, 1996
- Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvementJournal of the American Academy of Dermatology, 1995
- Antipsoriatic effect of fumaric acid derivativesJournal of the American Academy of Dermatology, 1994
- Fumaric acid therapy for psoriasis: A randomized, double-blind, placebo-controlled studyJournal of the American Academy of Dermatology, 1990
- Methotrexate in psoriasis: Revised guidelinesJournal of the American Academy of Dermatology, 1988
- Methotrexate guidelines—revisedJournal of the American Academy of Dermatology, 1982